Neumentum, Inc. is a privately held life science company focused on non-opioid alternatives to address pain. Neumentum is developing and plans to commercialize products that have the potential to effectively treat pain, without the risks of abuse, misuse, and diversion seen with opioid analgesics. Since founding the company in March of 2017, Neumentum has secured worldwide rights to six novel non-opioid products, including its lead product, NTM-001 (Toradol PMB) product. In October 2019, Neumentum entered into a global licensing agreement with Johnson & Johnson for the rights to a Phase 2 novel oral analgesic, NTM-006, plus a portfolio of backup compounds. Neumentum's lead product candidate, NTM-001 (novel, alcohol-free formulation of ketorolac in a pre-mixed bag for 24 hour continuous IV infusion), is prepared to enter phase 3 clinical trials and, if successfully approved by the FDA, has the potential to treat moderately severe acute pain requiring analgesia at the opioid level.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):